Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Bladder Overactive Clear all
Completed Phase 3 Interventional Results available

Fesoterodine "add-on" Male Overactive Bladder Study

NCT00546637
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older · Male only
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

NCT01157377
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
AGN-214868, AGN-214868 placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 16, 2026, 4:02 PM EDT
Recruiting Phase 3 Interventional

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299
View directory record Official record
Conditions
Overactive Bladder Syndrome, Neuropathic Bladder
Interventions
Oxybutynin Transdermal Patch, Oral Oxybutynin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years to 8 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery

NCT05820139
View directory record Official record
Conditions
Voiding Dysfunction
Interventions
Control Group, Test Group
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 16, 2026, 4:02 PM EDT
Not listed Not applicable Interventional

Painless Laser Therapy for Overactive Bladder

NCT01569061
View directory record Official record
Conditions
Overactive Bladder
Interventions
LCT-1000TM (Manufacturer: LiteCure)
Device
Lead sponsor
Zipper Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

NCT03017170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Dried Cranberry, Placebo Oral Capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Mirabegron and Urinary Urgency Incontinence

NCT02495389
View directory record Official record
Conditions
Overactive Bladder
Interventions
Mirabegron
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Overactive Bladder Telemedicine Non-inferiority Trial

NCT05117918
View directory record Official record
Conditions
Overactive Bladder
Interventions
SUFU Clinical Care Pathway for Overactive Bladder, Telemedicine
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks

NCT05557279
View directory record Official record
Conditions
Overactive Bladder
Interventions
500 mg NDS-446
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 16, 2026, 4:02 PM EDT
Withdrawn Phase 2 Interventional

Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.

NCT00262496
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
Botox
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 16, 2026, 4:02 PM EDT
Recruiting Not applicable Interventional

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

NCT06072703
View directory record Official record
Conditions
Neurogenic Bladder, Multiple Sclerosis, Overactive Bladder
Interventions
Magstim Rapid2 System
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

NCT03583372
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, placebos, Tolterodine Tartrate ER
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
107
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 16, 2026, 4:02 PM EDT
Recruiting Not applicable Interventional

Tensi+ for Treating Overactive Bladder

NCT07300904
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Tensi+
Device
Lead sponsor
Stimuli Technology
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Beverly Hills, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00662909
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 16, 2026, 4:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair

NCT02502838
View directory record Official record
Conditions
Overactive Bladder, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
22 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 16, 2026, 4:02 PM EDT
Withdrawn Phase 4 Interventional

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

NCT05393921
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Intravesical Botox injection
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio • Lyndhurst, Ohio • Richmond Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 16, 2026, 4:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Urinary Cytokines in Patients With Overactive Bladder (OAB)

NCT00868621
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infection
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder

NCT00912314
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
PTNS
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 16, 2026, 4:02 PM EDT
Not listed Early Phase 1 Interventional

Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence

NCT05099419
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

NCT00425100
View directory record Official record
Conditions
Overactive Bladder
Interventions
fesoterodine fumarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
24
States / cities
Homewood, Alabama • Huntsville, Alabama • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 16, 2026, 4:02 PM EDT
Completed No phase listed Observational

Tactile Imaging and Electromyography

NCT03477214
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Biomechanical and electromyography mapping
Diagnostic Test
Lead sponsor
Advanced Tactile Imaging, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Princeton, New Jersey • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Results available

Study of V117957 in Overactive Bladder Syndrome

NCT06024642
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
V117957, Placebo
Drug
Lead sponsor
Imbrium Therapeutics
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Canoga Park, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 4 Interventional

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

NCT00127270
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Darifenacin, Behavioral therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Timeline
2005 – 2006
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Sep 16, 2026, 4:02 PM EDT